Clinical trials: COVID-19 Booster
COVID-19
PROmotion of COVID-19 BOOSTer VA(X)Ccination in the Emergency Department - PROBOOSTVAXED
The goal of this cluster randomized clinical trial is to test the efficacy of messaging interventions to increase booster vaccine uptake in adults in the emergency department(ED).
- Trial name
- PROBOOSTVAXED (NCT06156215)
- Testing
- Vaccine Messaging, Vaccine Acceptance Question
- Where
- 7 sites in United States
- Volunteers
- 919 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
COVID-19
IH Convidecia as Second Booster Dose Against Breakthrough Infections
This will be a randomized single-blind controlled trial to determine the immunogenicity, efficacy and safety of IH Convidecia (CanSino), as a second booster vaccination against Omicron and other emerging VOCs to prevent…
- Trial name
- NCT05517642
- Testing
- Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH), mRNA vaccine BNT162b2 (Pfizer)
- Where
- Malaysia
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
COVID-19
Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of BBIBP-CorV
Study objectives: To evaluate the immunogenicity and immunity persistence and safety of recombinant novel coronavirus vaccine (CHO cells) after booster immunization in populations vaccinated with two doses of marketed novel…
- Trial name
- NCT05205083
- Testing
- Recombinant novel coronavirus vaccine (CHO cells)
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19
Safety and Immunogenicity Trial of MPV/S-2P SARS-CoV-2 Vaccine in Adults
A clinical trial to evaluate the safety, reactogenicity, and immunogenicity of MPV/S-2P administered intranasally to adults who have previously received a primary series and at least one booster with an authorized or licensed…
- Trial name
- NCT06441968
- Testing
- MPV/S-2P
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV 2 Infection, Covid19
Safety and Efficacy of COVID-19 Prime-boost Vaccine in Bahrain
Coronavirus disease 2019 (COVID-19) is potentially a deadly disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that targets the lung mainly, resulting in respiratory tract infections in humans.
- Trial name
- NCT04993560
- Testing
- BBIBP-CorV, BNT162b2
- Where
- Bahrain
- Volunteers
- 305 people
- Sponsor
- Royal College of Surgeons in Ireland - Medical University of Bahrain
Myocarditis
Incidence, Patient Characteristics and Outcome of Myocarditis After COVID-19 mRNA Vaccine
This study evaluates the incidence, patient characteristics and outcome of myocarditis after the COVID-19 mRNA vaccination in healthcare professionals.
- Trial name
- MACIS (NCT05438472)
- Testing
- data collection in healthcare professionals with COVID-19 mRNA vaccine booster
- Where
- Switzerland
- Volunteers
- 835 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Healthy Adults
An Experimental Medicine Multicenter Trial to Evaluate the Safety and Immunogenicity of Experimental Versus Authorized SARS-CoV-2 Vaccine Candidates as a Booster Dose in Healthy Participants Previously Vaccinated With Authorized mRNA SARS-CoV-2 Vaccines.
The SOLVE-01 trial is a study evaluating four SARS-CoV-2 vaccines as booster injections: two experimental vaccines (CD40.RBDv and CD40.Pan.CoV, both combined with the Hiltonol® adjuvant) and two authorised vaccines (Comirnaty®…
- Trial name
- SOLVE-01 (NCT07605520)
- Testing
- CD40.RBDv vaccine adjuvanted with Hiltonol®, CD40.Pan.CoV vaccine adjuvanted with Hiltonol®, Comirnaty® vaccine
- Where
- 3 sites in France, Switzerland
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Kidney Diseases, Kidney Transplant; Complications
Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.
Prospective observational trial to assess immunological safety (anti-HLA antibodies, donor-derived cell-free DNA) and immunological effectiveness (anti-SARS-CoV-2 IgG) of the first booster dose of SARS-CoV-2 mRNA vaccines in…
- Conditions
- Kidney Diseases, Kidney Transplant; Complications, COVID-19, Vaccine Adverse Reaction
- Trial name
- NCT05483725
- Testing
- Booster dose of mRNA vaccine
- Where
- Czechia
- Volunteers
- 108 people
- Sponsor
- Institute for Clinical and Experimental Medicine
COVID19
Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)
This study is a continuation study of the original V-01-I phase trial, using a single-center, single-arm, open design to evaluate the immunogenicity and safety of the third dose booster immunization of Recombinant SARS-CoV-2…
- Trial name
- NCT05050474
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Kidney Transplant Recipient
Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients
The purpose of this research is to see if a dose of the Janssen Ad26.CoV2.S vaccine effects the immune protection in individuals who have had a kidney transplant and two or three doses of mRNA vaccine (Pfizer and/or Moderna…
- Trial name
- NCT05220397
- Testing
- Janssen Ad26.CoV2.S Vaccine, Reduction in Immunosuppression Medication, Maintenance in Immunosuppression Medication
- Where
- 3 sites in United States
- Volunteers
- 468 people
- Sponsor
- Mark Stegall
Anti-SARS-CoV-2 Antibody Response
Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies After COVID-19 Booster Vaccines
The investigators aim to evaluate the ability of a COVID-19 (Coronavirus disease) booster vaccine to induce a salivary antibody response and investigate a possible correlation with the serum antibody response and the cellular…
- Trial name
- CoVVacBoost (NCT05142540)
- Testing
- blood and saliva samples will be taken
- Where
- Austria
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
SARS-CoV-2 Infection, COVID-19
Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People
This was an exploratory Phase I, randomized, observer-blind, active-controlled, dose-escalation trial to evaluate four dose levels (DLs) of BNT162b4 given in combination with BNT162b2 Bivalent (original/Omicron BA.4/BA.5) to…
- Trial name
- NCT05541861
- Testing
- BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg, BNT162b4 5 mcg, BNT162b4 10 mcg
- Where
- 17 sites in United States
- Volunteers
- 383 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Covid-19 Vaccine
A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.
This is a Phase II/III, randomized, double-blinded study in adults ≥ 18 years old who received 2 or more doses of inactivated COVID-19 vaccine to evaluate the efficacy, safety and immunogenicity of a booster dose of PIKA COVID-19…
- Trial name
- NCT05463419
- Testing
- PIKA COVID-19 vaccine, Inactivated Covid-19 vaccine
- Where
- 6 sites in Philippines, United Arab Emirates
- Volunteers
- 5,860 people, healthy volunteers welcome
- Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.
COVID-19
Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in Adults
This phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of STX-S in adults who have previously received a primary series and at least one booster with an authorized or licensed SARS-CoV-2…
- Trial name
- NCT07095231
- Testing
- STX-S
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV-2
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters
The main goal of Part A of this study is to assess the safety, reactogenicity, and immunogenicity of the study vaccine candidates.
- Trial name
- NCT05137236
- Testing
- mRNA-1283, mRNA-1283.211, mRNA-1273
- Where
- 17 sites in United States
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19
COVID-19 Bivalent Booster Megastudy
This megastudy is a massive randomized controlled trial. By randomizing participants to 10 different intervention conditions simultaneously, the investigators will be able to compare the effectiveness of different interventions…
- Trial name
- NCT05607082
- Testing
- COVID Booster text messages
- Where
- United States
- Volunteers
- 2,600,000 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
COVID-19 Respiratory Infection
Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster Dose
A total sample size of 875 healthy volunteers ages ≥18 years will be recruited in this study in the ratio of 2:1:2:1:1. Group 1: (BBV154 in COVAXIN recipients): In this group, 250 participants will be recruited and administered…
- Trial name
- NCT05567471
- Testing
- BBV154 Intranasal Vaccine, Intramuscular vaccine COVAXIN, Covishield
- Where
- 9 sites in India
- Volunteers
- 875 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
COVID-19
Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines
This is an open-label Phase 3 study evaluating the immunogenicity and safety of Novavax vaccine(s) with Matrix-M™ adjuvant (ancestral strain NVX-CoV2373 and an alternative strain and/or multivalent Novavax vaccine) as booster…
- Trial name
- NCT05875701
- Testing
- NVX-CoV2373, SARS-CoV-2 rS antigen/Matrix-M Adjuvant
- Where
- 5 sites in United States
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID-19, Healthy
GLS-5310 Vaccine in Healthy Volunteers as a Booster for SARS-CoV-2 (COVID-19)
Phase I study to assess the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine given as a booster to those previously vaccinated against SARS-CoV-2
- Trial name
- NCT05182567
- Testing
- GLS-5310 (Group 1), GLS-5310 (Group 2), GLS-5310 (Group 3)
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
SARS-CoV-2
A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.
This study will be a phase-1, open-label, placebo-controlled, evaluation of two-dosages of a live, recombinant Newcastle disease virus expressing the spike protein of SARS-CoV-2 (NDV-HXP-S), an investigational product for IN, IM…
- Trial name
- NCT05181709
- Testing
- Sodium Chloride, NDV-HXP-S IN low dose, NDV-HXP-S IM low dose
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Sean Liu